Brookmont Capital Management Purchases 4,896 Shares of Novo Nordisk A/S (NYSE:NVO)

Brookmont Capital Management boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,309 shares of the company’s stock after purchasing an additional 4,896 shares during the period. Novo Nordisk A/S comprises approximately 2.0% of Brookmont Capital Management’s investment portfolio, making the stock its 14th biggest position. Brookmont Capital Management’s holdings in Novo Nordisk A/S were worth $3,811,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Mitchell & Pahl Private Wealth LLC boosted its stake in Novo Nordisk A/S by 3.5% in the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 12,599 shares of the company’s stock valued at $1,084,000 after buying an additional 424 shares in the last quarter. Ballentine Partners LLC lifted its stake in Novo Nordisk A/S by 6.9% in the 4th quarter. Ballentine Partners LLC now owns 28,589 shares of the company’s stock valued at $2,459,000 after purchasing an additional 1,854 shares during the last quarter. Martel Wealth Advisors Inc acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $516,000. ZWJ Investment Counsel Inc. boosted its position in Novo Nordisk A/S by 25.9% in the fourth quarter. ZWJ Investment Counsel Inc. now owns 2,384 shares of the company’s stock valued at $205,000 after buying an additional 491 shares in the last quarter. Finally, Koshinski Asset Management Inc. grew its stake in shares of Novo Nordisk A/S by 5.6% during the fourth quarter. Koshinski Asset Management Inc. now owns 12,254 shares of the company’s stock worth $1,054,000 after buying an additional 645 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $78.74 on Tuesday. The firm’s fifty day simple moving average is $97.76 and its two-hundred day simple moving average is $116.89. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.